Baystreet.ca RSS Feed http://www.baystreet.ca/rss/MasterRSS.aspx en-us Copyright (c) 2021 Baystreet.ca Inc. All rights reserved. 5/15/2021 7:57:18 AM <![CDATA[Lundin Gold "BUY"]]>Fri, 14 May 2021 11:59:00 ESThttps://www.baystreet.ca/articles/analyst_ratings.aspx?66997<![CDATA[Gold Eases on Firmer U.S. Dollar]]>Fri, 14 May 2021 06:37:00 ESThttps://www.baystreet.ca/articles/commodities.aspx?id=4711Friday, May 14, 2021


Gold Eases on Firmer U.S. Dollar


Gold edged lower on Friday, as a firmer dollar made bullion more expensive for other currency holders, although a pullback in the U.S. Treasury yields limited losses for the safe-haven metal.

Spot gold was down 0.2% at $1,823.77 U.S. per ounce overnight Friday. Bullion lost 0.4% so far this week.

U.S. gold futures were steady at $1,823.20.

The U.S. dollar index held firm near a one-week high, and was set for a weekly gain against its rivals.

Benchmark U.S. 10-year Treasury yields slipped from a more than one-month high hit on Thursday. Lower bond yields reduce the opportunity cost of holding non-interest bearing gold.

Data on Thursday showed that fewer Americans filed new claims for unemployment benefits last week, while producer prices increased more than expected in April.

Recent economic readings out of the United States have sparked concerns over rising inflation and raised bets over an earlier-than-expected Federal Reserve rate hike.

The U.S. central bank has pledged to keep interest rates low until the economy reaches full employment, and inflation hits 2% and is on track to "moderately" exceed that level for some time.

Gold tends to benefit from lower interest rate environment as it reduces the opportunity cost of holding non-yielding bullion.

Palladium gained 0.7% to $2,883.71 U.S> per ounce, but was on track to post a second straight weekly loss with a drop of about 2%.

Silver was flat at $27.06 U.S. per ounce, while platinum was up 0.6% at $1,212.88 U.S.

]]>
<![CDATA[Chip Shortage To Cost Auto Industry $110 Billion U.S. In Lost Revenue ]]>Fri, 14 May 2021 07:16:00 ESThttps://www.baystreet.ca/articles/techinsider.aspx?id=2888Friday, May 14, 2021

Chip Shortage To Cost Auto Industry $110 Billion U.S. In Lost Revenue


The ongoing semiconductor chip shortage is forecast to cost the global automotive industry $110 billion U.S. in lost revenue this year, according to consulting firm AlixPartners.

The forecast is up by 81.5% from an initial forecast of $60.6 billion U.S., which the New York-based firm released in late January when the chip shortage began causing automakers to halt production at their manufacturing plants.

AlixPartners said a number of factors have contributed to its upwardly revised forecast, including a fire at a plant near Tokyo, Japan for chip supplier Renesas and weather-related kinks in the automotive supply chain.

AlixPartners is forecasting that production of 3.9 million vehicles will be lost this year as a result of the semiconductor chip shortage. That’s up from January’s forecast that estimated the shortage would cut production of 2.2 million vehicles.

In the U.S., the shortage has caused the Biden administration to order a 100-day review of U.S. supply chains. About $50 billion U.S. of President Joe Biden’s $2-trillion U.S. infrastructure proposal is earmarked for the American semiconductor industry.

Automakers such as Ford (NYSE:F) and General Motors (NYSE:GM) expect the chip shortage to cut billions of their earnings this year. Ford said the situation will lower its earnings by about $2.5 billion U.S. in 2021. GM expects the chip shortage will cut its earnings by $1.5 billion U.S. to $2 billion U.S.

Semiconductor chips are important components of new vehicles in areas such as infotainment systems and power steering. AlixPartners says it expects the largest impact to production in the second quarter of this year and that the situation will gradually improve during the second half of the year and into 2022.

]]>
<![CDATA[Economic Calendar]]>Sat, 15 May 2021 07:57:18 ESThttps://www.baystreet.ca/articles/econ_calendar.aspx?id=18125May 2021
 

DATE

STATISTIC FOR CURRENT MONTH PREVIOUS MONTH
Monday, May 3, 2021 Markit Canada Manufacturing PMI: 9:30 am April The headline seasonally adjusted IHS Markit Canada Manufacturing Purchasing Managers’ Index registered 57.2 in April, down from 58.5 in March, to signal the third-strongest growth in operating conditions in the survey to date, which began in October 2010. The headline seasonally adjusted IHS Markit Canada Manufacturing Purchasing Managers’ Index® (PMI®) registered 58.5 in March, up considerably from 54.8 in February, to become the highest reading in over 10 years of data collection.
Tuesday, May 4, 2021 Building Permits: 8:30am Mar March marked the third consecutive month of record-setting numbers as building permits rose 5.7% to $10.9 billion, reflecting a booming residential sector. The total value of building permits issued in February broke the $10 billion mark for the first time, as a jump in the non-residential sector more than offset the decline in the residential sector.
Tuesday, May 4, 2021 Canadian International Merchandise Trade: 8:30am Mar In March, Canada's imports posted a significant increase of 5.5%, while exports edged up 0.3%. As a result, following two consecutive monthly trade surpluses, Canada's merchandise trade balance returned to a deficit position, moving from a surplus of $1.4 billion in February to a deficit of $1.1 billion in March. Canada's merchandise exports decreased by 2.7% in February, while imports fell 2.4%. As a result, Canada's merchandise trade surplus with the world narrowed from $1.2 billion in January to $1.0 billion in February.
Friday, May 7, 2021 Labour Force Survey: 8:30am April Employment fell by 207,000 (-1.1%) in April and the unemployment rate rose 0.6 percentage points to 8.1%. Employment rose 303,000 (or 1.6%) in March. Combined with an increase of 259,000 (1.4%) in February, this brought employment to within 1.5% (-296,000) of its February 2020 level. The unemployment rate fell 0.7 percentage points to 7.5%, the lowest level since February 2020.
Friday, May 7, 2021 IVEY Purchasing Managers Index: 10:00am April The index tumbled to 60.6 in April, lurching below the 72.9 reading in March, but still well above the 22.8 figure for April 2020 The index catapulted to 72.9 in March, towering above the 60.0 reading in February, and racing away from the 26.0 figure for March 2020
Friday, May 14, 2021 Wholesale Trade: 8:30am Mar Sales by Canadian wholesalers rose 2.8% in March, the second increase in three months. Sales of wholesale products fell 0.7% in February to $68.8 billion, the second decline in three months. Despite the drop, sales in February were the second highest on record for the sector.
Friday, May 14, 2021 Monthly Survey of Manufacturing: 8:30am Mar Manufacturing sales bounced back in March, rising 3.5% to $57.8 billion, following a 1.1% decline in February. Gains were widespread across all major industries. Manufacturing sales decreased 1.6% to $55.4 billion in February, following a 3.4% increase in January. Lower sales of motor vehicles and motor vehicle parts were largely responsible for the decline.
Saturday, May 15, 2021 CREAstats - MLS Sales: 8:30am April --- Home sales recorded over Canadian MLS® Systems climbed 5.2% between February and March 2021 to set another new all-time record.
Monday, May 17, 2021 Canada's International Transactions in Securities: 8:30am Mar --- Canadian investors acquired $10.5 billion of foreign securities in February, continuing a trend of net purchases that began in May 2020. Meanwhile, foreign investment in Canadian securities reached $8.5 billion, led by strong acquisitions of Canadian shares.
Monday, May 17, 2021 Housing Starts: 8:15am April --- The trend in housing starts was 273,664 units in March 2021, up from 252,636 units in February 2021, according to Canada Mortgage and Housing Corporation (CMHC).
Wednesday, May 19, 2021 Consumer Price Index: 8:30am April --- CPI rose 2.2% on a year-over-year basis in March, up from a 1.1% gain in February. On a seasonally adjusted monthly basis, the CPI rose 0.1% in March.
Thursday, May 20, 2021 New Housing Price Index: 8:30am April --- New home prices rose 1.1% in March nationally, following one of the largest monthly increases on record in February.
Friday, May 21, 2021 Retail Trade: 8:30am Mar --- Retail sales were up 4.8% to $55.1 billion in February. Sales increased in nine of 11 subsectors, led by higher sales at motor vehicle and parts dealers and gasoline stations.
Thursday, May 27, 2021 Payroll Employment, Earnings and Hours: 8:30am Mar --- The total number of payroll employees in February was down 1.2 million (-6.8%) from one year earlier, before the onset of the COVID-19 pandemic.
Monday, May 31, 2021 Industrial Product Price Index: 8:30am April --- In March, the Industrial Product Price Index increased 1.6% month over month and 10.0% year over year
Monday, May 31, 2021 Raw Materials Price Index: 8:30am April --- The Raw Materials Price Index was up 2.3% month over month and up 34.7% year over year.
Tuesday, June 1, 2021 GDP: 8:30am Mar --- Real gross domestic product grew 0.4% in February, following 0.7% growth in January, as 14 of the 20 industrial sectors were up.
Wednesday, June 9, 2021 BoC Interest Rate Decision: 10:00am June --- The Bank of Canada today held its target for the overnight rate at the effective lower bound of 0.25%, with the Bank Rate at 0.5%and the deposit rate at 0.25%
]]>
<![CDATA[Greyhound Canada Ceases Operations]]>Fri, 14 May 2021 06:24:00 ESThttps://www.baystreet.ca/articles/economiccommentary.aspx?id=3200Greyhound Canada Ceases Operations


It’s the end of an era as Greyhound Canada is permanently shutting down all of its bus routes across the country and ceasing operations.

The bus company ended its remaining routes in Ontario and Quebec on Thursday (May 13). Greyhound Canada had been in operation for nearly a century.

The company’s American affiliate, Greyhound Lines, Inc., will continue to operate cross-border routes to Toronto, Montreal and Vancouver once the border reopens.

The decision to shutdown all operations comes a year after Greyhound Canada temporarily suspended all service due to a sharp decline in passengers and mounting travel restrictions amid the pandemic. The bus carrier has struggled for years with declining ridership, increasing competition and deregulation.

But the complete loss of farebox revenue during the pandemic has forced the company to permanently cease operations. The decision is a blow to rural and remote areas that rely on private intercity bus companies for transportation.

Greyhound Canada had long been part of a network linking smaller communities and big cities, offering an affordable and convenient mode of travel. The rise of car ownership, ride sharing, discount airlines and urban migration has eroded bus ridership.

Citing declining ridership, deregulation and subsidized competition, Greyhound Canada had already suspended all operations in Western Canada in 2018. Yet despite the ongoing challenges with its remaining routes, nothing could have prepared the company for the dramatic 95% drop in passengers at the outset of the pandemic.

About 260 employees were laid off after Greyhound Canada temporarily ended its passenger service in May 2020. An additional 45 employees will be laid off because of the permanent closure, the company said.


]]>
<![CDATA[Asia Recovers to End Week ]]>Fri, 14 May 2021 06:56:00 ESThttps://www.baystreet.ca/articles/foreignmarketwrap.aspx?id=3670Friday, May 14, 2021

Asia Recovers to End Week


Stocks in Asia-Pacific mostly rose on Friday, following an overnight bounce for stocks stateside.

In Japan, the Nikkei 225 regained 636.46 points, or 2.3%, to 28,084.47.

The Japanese yen traded at 109.33 per U.S. dollar, after weakening earlier in the week from below 109 against the greenback.

In Hong Kong, the Hang Seng index regrouped 308.9 points, or 1.1%, to 28,027.57.

Hong Kong-listed shares of Chinese tech giant Alibaba plunged 4% on Friday after the firm posted its first operating loss as a public company in its fiscal fourth quarter.

The losses came after the Southeast Asian nation said Friday it’s “very likely” that the air travel bubble with Hong Kong will not start on May 26 as planned. The government also announced there will be more COVID-19 restrictions starting this weekend, following a recent rise in local infections.

The Singapore dollar weakened about 0.1% against the greenback, trading at 1.3346 per dollar. Shares of Singapore Airlines plunged 5.7%, while Cathay Pacific’s stock in Hong Kong edged 0.3% higher.

The Australian dollar was at $0.7742, having declined from levels above $0.78 earlier this week.

In other markets

In Shanghai, the CSI 300 recovered 117.62 points, or 2.4%, to 5,110.59.

In Singapore, the Straits Times index returned to trading with a loss of 68.24 points, or 2.2%, to 3,055.02.

In Taiwan, the Taiex index added 156.09 points, or 1 %, to 15,827.09

In Korea, the Kospi index gained 31.21 points, or 1%, to 3,153.32

In New Zealand the NZX 50 fell 60.26 points, or 0.5%, to 12,367.86

In Australia, the ASX 200 picked up 31.52 points, or 0.5%, to 7,014.24

]]>
<![CDATA[U.S. Retail Sales Flat in April ]]>Fri, 14 May 2021 11:23:00 ESThttps://www.baystreet.ca/articles/globalmarkets.aspx?id=2872Tills in U.S. retail stores did not move quickly last month.

Figures released Friday by the U.S. Commerce Department showed retail sales unexpectedly stalled in April as the boost from stimulus checks faded, but an acceleration is likely in the coming months amid record savings and a reopening economy.

The department said on Friday the unchanged reading in retail sales last month followed a 10.7% surge in March, an upward revision from the previously reported 9.7% increase.

Economists had forecast retail sales would rise 1.0%. Economists polled by Dow Jones had expected a more modest 0.8% increase.

Many qualified households received additional $1,400 checks in March, which were part of the White House’s $1.9 trillion COVID-19 pandemic rescue package approved early that month.

Retail sales account for the goods component of consumer spending, with services such as health-care, education, travel and hotel accommodation making up the other portion. Households have accumulated at least $2.3 trillion in excess savings during the pandemic, which should underpin spending this year.

]]>
<![CDATA[TSXV New Listings]]>Fri, 17 Jan 2020 06:20:00 ESThttps://www.baystreet.ca/articles/ipo_tsx.aspx?id=10023 Company Name Ticker Date ANC Capital Ventures Inc. ANCV.P 17-01-2020 Vincero Capital Corp VCO.P 07-02-2020 Good2Go2 Corp. GOAL.P 13-02-2020 Eclipse Gold Mining Corporation EGLD 18-02-2020 Spectre Capital Corp. SOO.P 21-02-2020 Aphelion Capital Corp. APHE.P 26-02-2020 Canada Nickel Company Inc. CNC 27-02-2020 E36 Capital Corp. ETSC.P 28-02-2020 Zenith Capital Corporation ZENI.P 06-03-2020 Baltic I Acquisition Corp. BLTC.P 11-03-2020 Hansco Capital Corp. HCO.P 12-03-2020 Hakken Capital Corp. HAKK.P 13-03-2020 Moon River Capital Ltd. MOO.P 20-03-2020 Fosterville South Exploration Ltd. FSX 14-04-2020 Newtopia Inc. NEWU 04-05-2020 Standard Uranium Ltd. STND 04-05-2020 Trillium Acquisition Corp. TCK.P 05-05-2020 Israel Capital Canada Corp. IL.P 08-05-2020 Spectra7 Microsystems Inc. SEV 22-05-2020 Whatcom Capital Corp. WHAT.P 02-06-2020 CloudMD Software & Services Inc. DOC 04-06-2020 Freeform Capital Partners Inc. FRM.P 17-06-2020 Kalon Acquisition Corp. KAC.P 26-06-2020 Blue Rhino Capital Corp. RHNO.P 13-07-2020 Lamaska Capital Corp. LCC.P 13-07-2020 Solaris Resources Inc. SLS 13-07-2020 RIWI Corp. RIWI 27-07-2020 New Found Gold Corp. NFG 11-08-2020 GHP Noetic Science-Psychedelic Pharma Inc. PSYF.P 11-08-2020 Ridgeline Minerals Corp. RDG 13-08-2020 Valencia Capital Inc. VAL.P 14-08-2020 Sun Peak Metals Corp. PEAK 17-08-2020 Capitan Mining Inc. CAPT 21-08-2020 Spartan Acquisition Corp. VDKA.P 31-08-2020 Reitmans (Canada) Limited RET 03-09-2020 Altina Capital Corp. ALTN.P 21-09-2020 Deveron Corp. FARM 21-09-2020 Altina Capital Corp. ALTN.P 21-09-2020 Marwest Apartment Real Estate Investment Trust MAR.P 22-09-2020 Rubicon Organics Inc. ROMJ 22-09-2020 Exro Technologies Inc. EXRO 22-09-2020 Stormcrow Holdings Corp. CROW.P 23-09-2020 Nova Royalty Corp. NOVR 01-10-2020 Carebook Technologies Inc. CRBK 06-10-2020 Justify Capital Corp. JST.P 15-10-2020 Montage Gold Corp. MAU 23-10-2020 VLCTY Capital Inc. VLCY.P 28-10-2020 kadestone Capital Corp. KDSX 29-10-2020 Pivotree Inc. PVT 30-10-2020 Hapbee Technologies, Inc. HAPB 30-10-2020 High Mountain 2 Capital Corporation HMCC.P 05-11-2020 High Tide Inc. HITI 19-11-2020 AIM5 Ventures Inc. AIME.P 24-11-2020 Whitehorse Gold Corp. WHG 25-11-2020 Element 29 Resources Inc. ECU 03-12-2020 Tempus Resources Ltd. TMRR 07-12-2020 Cuspis Capital II Ltd. CCII.P 11-12-2020 Jabbo Capital Corp. JAB.P 14-12-2020 Cross Border Capital I Inc. CBX.P 22-12-2020 EFH Holdings Inc. EFH 23-12-2020 Empress Royalty Corp. EMPR 29-12-2020 E2Gold Inc. ETU 30-12-2020 Skylight Health Group Inc. SHG 06-01-2021 HAW Capital 2 Corp. HAW.P 08-01-2021 Summa Silver Corp. SSVR 11-01-2021 Compass Venture Inc. CVI.P 21-01-2021 Railtown Capital Corp RLT.P 28-01-2021 Topicus.com Inc. TOI 01-02-2021 Leviathan Gold Ltd. LVX 10-02-2021 Aumento Capital VIII Corp. AMU.P 17-02-2021 Jesmond Capital Ltd. JES.P 18-02-2021 Jesmond Capital Ltd. JES.P 19-02-2021 Star Royalties Ltd. STRR 19-02-2021 Gravitas One Capital Corp. GONE.P 22-02-2021 County Capital 2 Ltd. CTWO.P 23-02-2021 Four Arrows Capital Corp. AROW.P 25-02-2021 Zacatecas Silver Corp. ZAC 02-03-2021 Avalon Works Corp. AWB 03-03-2021 SPC Nickel Corp. SPC 08-03-2021 Mednow Inc. MNOW 08-03-2021 AF2 Capital Corp. AF.P 15-03-2021 The Very Good Food Company Inc. VERY 17-03-2021 Mayfair Gold Corp. MFG 22-03-2021 Starlight U.S. Multi-Family (No.2) Core Plus Fund SCPT.A 31-03-2021 Apolo IV Acquisition Corp. AIV.P 01-04-2021 Great Bear Royalties Corp. GBRR 05-04-2021 POCML 6 Inc. POCC.P 06-04-2021 Cannara Biotech Inc. LOVE 08-04-2021 Anacott Acquisition Corporation AAC.P 13-04-2021 Rider 2 Investment Capital Corp. RIDR.P 14-04-2021 New Target Mining Corp. NEW 15-04-2021 Just Kitchen Holdings Corp. JK 15-04-2021 Sierra Madre Gold and Silver Ltd. SM 19-04-2021 Germinate Capital Ltd. GCAP.P 20-04-2021 Nobel29 Resources Corp NBLC 20-04-2021 Goldplay Mining Inc. AUC 21-04-2021 Pivotal Financial Corp. PIV.P 23-04-2021 SRHI Inc. SRHI 27-04-2021 K.B. Recycling Industries Ltd. AKMY 28-04-2021 Monumental Gold Corp. MGLD 30-04-2021 AIM6 Ventures Inc. AIMF.P 30-04-2021 Momentous Capital Corp. MCC.P 03-05-2021 American Eagle Gold Corp. AE 03-05-2021 Evolve FANGMA Index ETF TECH 05-05-2021 Millennial Precious Metals Corp. MPM 05-05-2021 Mercury Acquisitions Corp. MERC.P 11-05-2021 Cedarmont Capital Corp. CCCA.P 13-05-2021 Dash Capital Corp. DCX.P 14-05-2021]]><![CDATA[TSX Gains Take some of the Sting out of Weekly Losses ]]>Fri, 14 May 2021 04:19:00 ESThttps://www.baystreet.ca/articles/marketupdates.aspx?id=10222Friday, May 14, 2021

16:19 PM EST
TSX Gains Take some of the Sting out of Weekly Losses

MEG, Kinross in Focus



Equities in Canada’s largest sector got bruised on the week, but Friday’s gains eased some of the blow, as energy and gold stocks staged impressive rallies.

The TSX rumbled ahead 229.48 points, or 1.2%, to close Friday at 19,365.29. However, the index fell short on the week by 107 points, or 0.55%

The Canadian dollar gained 0.37 cents at 82.54 cents U.S.

Energy stocks were the big winners on the day, with MEG Energy towering 53 cents, or 7.8%, to $7.29, while Vermilion Energy gained 37 cents, or 4.1%, to $9.36.

Among gold plays, Kinross Gold hiked 28 cents, or 3.1%, to $9.41, while Seabridge Gold tacked on 73 cents, or 3.5%, to $21.91.

In health-care Aurinia Pharmaceuticals rose $1.07, or 8%, to $14.42, while Canopy Growth added 85 cents, or 3.2%, to $27.76.

On the economic platform, manufacturing sales bounced back in March, rising 3.5% to $57.8 billion, following a 1.1% decline in February. Gains were widespread across all major industries.

Sales by Canadian wholesalers rose 2.8% in March, the second increase in three months. The growth in March was due to increases in the building material and supplies sub-sector and the miscellaneous sub-sector.

ON BAYSTREET

The TSX Venture Exchange zoomed 22.61 points, or 2.5%, to end Friday at 930.96, minimizing the loss on the week to 19 points, or 2%.

All 12 subgroups were positive on the day, with energy stocks gushing 2.8%, gold shining 2.3% brighter, and health-care stronger 2.1%.

ON WALLSTREET

U.S. stocks jumped on Friday, rebounding for a second day led by technology shares and reopening trades after Wall Street started the week with big losses.

The Dow Jones Industrials soared 360.62 points, or 1.1%, to 34,382.07.

The S&P 500 gained 61.36 points, or 1.5%, to 4,173.86.

The NASDAQ jumped 304.99 points, or 2.3%, to 13,429.98.

The major averages experienced a roller-coaster week that saw the blue-chip Dow drop nearly 1,200 points from Monday to Wednesday. The S&P 500 lost 4%, and the NASDAQ fell 5% during that period.

The indexes have since rebounded from the steep selloff, but they still posted modest losses for the week as inflation fears hit sentiment.

The Dow and the S&P 500 fell more than 1% each this week, while tech stocks got hit especially hard, pulling the NASDAQ down over 2.3% for the week.

Tech stocks were the biggest outperformers Friday. Tesla gained more than 3%. Facebook jumped 3.5%, while Alphabet and Microsoft rose more than 2%. Apple, Amazon and Netflix also all climbed over 1%.

Disney shares were bucking the trend, falling 4.5% after posting weaker-than-expected revenue and streaming subscribers.

United Airlines and American Airlines both climbed more than 5%. Carnival and Norwegian Cruise Line shares both popped more than 8%, while Royal Caribbean advanced more than 7%.

Stocks most exposed to the ongoing recovery jumped again Friday after the Centers for Disease Control and Prevention eased guidelines saying that in most settings fully vaccinated people don’t need to wear masks indoors or outdoors.

Stocks advanced on Friday even after data showed consumer purchases slowed down last month. Advance retail sales were flat for April, the Commerce Department reported Friday. That compared to the Dow Jones estimate of a 0.8% gain and a 9.8% surge in March.

Prices for 10-Year Treasurys moved higher, thus lowering yields to 1.63% from Thursday’s 1.66%. Treasury prices and yields move in opposite directions.

Oil prices regained $1.53 to $65.35 U.S. a barrel.

Gold prices gained $19.50 to $1,843.50 U.S. an ounce.





]]>
<![CDATA[Stocks in Play: SNC-Lavalin Group Inc.]]>Fri, 14 May 2021 03:21:36 ESThttps://www.baystreet.ca/articles/stocksinplay.aspx?id=32950Friday, May 14, 2021

15:21 PM EST - SNC-Lavalin Group Inc. : Announced first-quarter revenues of $1.5 billion. Segment Adjusted EBIT to revenue ratio of 8.6%, 13.9% and 5.8% for EDPM, Nuclear and Infrastructure Services, respectively, in line with Company's targets. Net cash generated from operating activities of $118 million. SNC-Lavalin Group Inc. (T.SNC ) shares were up $4.74 at 32.48.

]]>
<![CDATA[Alternative Crypto Stocks Delivering Innovative New Digital Currency Entry Points for Investors]]>Fri, 14 May 2021 11:32:42 ESThttps://www.baystreet.ca/articles/stockstowatch.aspx?id=10501Friday, May 14, 2021

Alternative Crypto Stocks Delivering Innovative New Digital Currency Entry Points for Investors


VANCOUVER – USA News Group – One of the world’s largest cryptocurrency exchanges is now officially publicly trading, having hit a valuation of more than US$85 billion. But while holding the digital currencies themselves might still be too new a concept for some investors to consider, the market is currently providing alternative entry points into crypto through options such a live streaming platform that provides users to participate in digital mining by Hello Pal International Inc. (CSE:HP) (OTC:HLLPF), mega corporations like Tesla, Inc. (NASDAQ:TSLA) that will be accepting Bitcoin, or direct mining operations such as Marathon Digital Holdings, Inc. (NASDAQ:MARA), Bit Digital, Inc. (NASDAQ:BTBT), or Canaan Inc. (NASDAQ:CAN).

Earlier in April 2020, the global cryptocurrency market topped $2 trillion for the first time. Among the hottest cryptocurrencies during the month was Dogecoin (DOGE), which defied all odds and surged 400% to a combined value worth $40 billion.

For users of the popular social media streaming platform Hello Pal International Inc. (CSE:HP) (OTC:HLLPF), now they can take part in the mining of DOGE as well as Litecoin (LTC)—thanks to a newly signed agreement to access 12,500 mining rigs dedicated to mining both DOGE and LTC.

"We’re ecstatic that our choice of cryptocurrencies to mine seems to have been validated especially by the recent incredible surge in market interest and activity of Dogecoin,” said KL Wong, Founder and Chairman of Hello Pal. “As far as we are aware, upon completion of this transaction, we shall be the only publicly listed company with primary exposure to Dogecoin."

The operation is at the forefront of these cryptocurrencies in particular, as it’s only been since February 2021 that a new chip was developed and announced to be capable of mining both Litecoin and Dogecoin simultaneously.

Hello Pal subsequently has the option to secure 100% interest in the operation. The newly-acquired Mining Assets deliver a combined hash rate of 6.25 TH/s, which amounts to 2.1% of the entire current LTC network hash rate.

"We are excited to expand our crypto strategy to also include Dogecoin and Litecoin, which we believe will play an increasingly important role in the cryptocurrency world going forward," said Hello Pal’s Founder and Chairman, KL Wong. "The Hello Pal community, especially what we envision for it to become, is a natural fit with the Dogecoin/Litecoin community, and this deal allows us to become a key player in it."

The public reaction Hello Pal’s involvement in the Dogecoin movement, resulted in an unprecedented surge in traffic of over 1000% to the official company website causing a website server overload and a temporary outage.

"The sharp increase in activity on our website and the Hello Pal app validates the clear position we have taken on Dogecoin as well as on cryptocurrency in general," added Wong.

There’s probably no more prominent figure in the cryptocurrency movement than Elon Musk, Founder and CEO of Tesla, Inc. (NASDAQ:TSLA). In particular, Musk has championed both Bitcoin (BTC) and DOGE.

Now the market is reacting to Tesla’s first set of results since adding $1.5 billion worth of BTC to its balance sheet—with a promise to increase its holdings.

According to Wedbush Securities analyst Daniel Ives back in February, “[Tesla is] on a trajectory to make more from its bitcoin investments than profits from selling its EV (electric vehicle) cars in all of 2020.”

And because the company also manufactures solar panels and batteries, the head of Ark Research is claiming Tesla has a significant “product opportunity” in attaching Bitcoin Mining equipment to their solar outfits.

Prior to the financials release, Musk teased the market by tweeting “What does the future hodl?”. And no, that wasn’t a typo—“hodl” is an intentionally misspelled meme used among the crypto crowd in place of the word “hold”.

Musk’s company may not be the only ones hinting at holding cryptocurrency. Crypto mining giant Marathon Digital Holdings, Inc. (NASDAQ:MARA) doesn’t convert its mined cyrptos into dollars—instead opting to hold them on their balance sheet.

According to H.C. Wainwright Analyst Kevin Dede, Marathon has “its paws on the top performing mining machines available in mass production, with claims on all to be manufactured through the March quarter 2022— a full year away.”

Dede also highlighted the company’s strong cash position (outside of the cryptocurrency), stating: “The 5-star analyst also notes the company’s strong cash position: “In combination with $212M of cash, Marathon sits well on top of the estimated $160-170M owed on the collection of Bitmain Antminer purchase contracts leading to the company's 103,000 miner fleet that should be up and running by the end of the March quarter next year, the largest in the publicly traded realm of bitcoin miners with which we are familiar."

North American miners Bit Digital, Inc. (NASDAQ:BTBT) recently announced the expansion of their bitcoin mining operations in North America. The expansion involves adding 40MW of hosting, and the deployment of an additional 13,000 ASIC miners at Compute North facilities in the United States.

"Compute North serves an important role in providing low-cost computing for customers like Bit Digital, while filling an important need for our energy partners," commented PJ Lee, co-founder and Chairman at Compute North. "The company's pioneering TIER 0™ data center design creates cost efficiencies and the flexibility to throttle power demand at each facility as required, making it a critical partner to the overall stability of local power grids as they bring more renewables online."

Not all miners are in the same positive situation, as Chinese-based Canaan Inc. (NASDAQ:CAN) is currently embroiled in the launch of dozens of class-action lawsuits (example) from angry shareholders.

The legal onslaught hasn’t deterred Canaan from carrying on with its operations, having announced a partnership with Cathay to launch a AI facial recognition module and AI chip in Japan, and a significant customer order of 11,760 BTC mining machines with Australian-based Mawson.

“Our contract with Mawson is a strong validation of our product quality, technology superiority, and supply reliability,” said Nangeng Zhang, Chairman and Chief Executive Officer of Canaan. “We look forward to forging a long-term relationship with Mawson and supporting the growth of its bitcoin mining operations around the world.”

Article Source: https://usanewsgroup.com/2020/11/16/live-streaming-is-taking-the-market-by-storm/

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Hello Pal International Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Hello Pal International Inc. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Hello Pal International Inc. which were purchased in the open market (a market cross) directly from the engagement of our agreement with the company. MIQ will not buy or sell shares of Hello Pal International Inc. for a minimum of 72 hours of this post date (November 17, 2020), but reserve the right to buy and sell, and will buy and sell shares of Hello Pal International Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

]]>
<![CDATA[USD/CAD - Canadian Dollar Opens Nearly Unchanged]]>Fri, 14 May 2021 03:14:08 ESThttps://www.baystreet.ca/articles/forex_trader.aspx?id=67020
The Australian dollar is the worst, having fallen 1.75% since Monday's open. USD/CAD bounced in a $1.2048-$1.2204 range, but the currency pair is not far from unchanged on the week despite the volatility.

Bank of Canada Governor Tiff Macklem is responsible for USD/CAD spiking to $1.2204 yesterday after he replied to a question about the currency’s value. He said that continued appreciation of the Canadian dollar could be a headwind to thebank's export projection and it could have a material impact on the economic outlook and monetary policy. Prices quickly retreated as Macklem was only stating the obvious.

The major Asia equity indexes closed with gains led by a 2.32% rise in Japan’s Nikkei 225. European stock markets are ticking higher into the U.S. Retail Sales data, and S&P 500 futures suggest a positive open for Wall Street. Crude oil and gold prices are firm, while 10-year Treasury yields are steady at 1.64%.

EURUSD traded in a $1.2072- $1.2128 range supported by softer 10-year U.S. Treasury yields and by the improved risk tone. EUR/USD has a positive bias above $1.20540.

GBP/USD bounced in $1.4038-$1.4075 range. Yesterday, Bank of England Governor Andrew Bailey said bank members are "already seeing a strong U.K. recovery" and that higher inflation will not persist. He added that interest rates would remain low.

USD/JPY continues to consolidate its post-U.S. Consumer Price Index gains, trading in a 109.26-109.65 range overnight as US inflation fears underpin prices.

AUD/USD consolidate earlier losses in a $0.7716-45 range and trades with a negative bias below 0.7760. AUD/USD is undermined by a drop in iron ore prices after reports China has told steel manufacturers to control price surges or face stiff penalties. NZD/USD outperformed its Australian cousin even though New Zealand Manufacturing Purchasing Managers Index dipped to 58.4.

Canada Manufacturing Sales are expected to rebound to 3.5% m/m in March after falling 1.6% in February.

Wholesale Sales will improve to 1.0% from a 0.7% drop. Neither report should have an impact on the Canadian dollar. The focus is on U.S. Retail sales, which analysts expect to rise 1.0% m/m in April. The result will be well below the 10% surge in March but strong enough to suggest the U.S. economy is recovering rapidly.

Rahim Madhavji is the President of KnightsbridgeFX.com, a Canadian currency exchange that provides better rates than the banks to Canadians
]]>
<![CDATA[Citigroup Vaults On Beating Quarterly Projections]]>Thu, 12 Oct 2017 10:07:02 ESThttp://www.baystreet.ca/articles.aspx?id=38460Earnings per Share came in for the quarter at $1.42, as opposed to $1.32 expected by experts. Revenue was $18.173 billion versus $17.896 billion expected. Fixed income trading: $2.877 billion versus a projected $2.84 billion

Said CEO Michael Corbat, "We had revenue increases in many of the products we have been investing in, tightly managed our expenses, and again saw loan growth in both our consumer and institutional businesses.”

Citi reported a 3% year-over-year increase in global consumer banking revenue. In North America, retail banking revenue rose 12%, excluding mortgages. Citi cited "continued growth in loans and assets under management," as well as higher interest rates.

The bank's international consumer business saw an 8% revenue increase, driven by higher loans and deposit volumes growth.

Citi's end-of-period loans, meanwhile, rose 2% to $653 billion, while deposits increased by 3% to $964 billion.

Shares of Citigroup have risen 26% this year, easily outperforming the broader market. The S&P 500 has gained 14% in 2017.

Citigroup's stock has also outperformed those of other big banks. Shares of JPMorgan Chase and Bank of America are up 11.9% and 16.9%,, respectively.

Folks who follow macroeconomic developments are also aware that Citigroup could benefit from tighter monetary policy in the near future. The U.S. Federal Reserve signaled a December rate hike in the summary of its Sept. 20 meeting.
Shares in C opened Thursday took on 31 cents to $75.25. ]]>
<![CDATA[Enterprise Group’s Hart Oilfield Rentals: Custom, Cost-Effective Infrastructure]]>Thu, 12 Oct 2017 09:51:46 ESThttp://www.baystreet.ca/articles.aspx?id=38459


Simply, if you are building a mining or oil business Hart rents customized equipment for project sites, drilling & completions and facilities that require mobile infrastructure.

It makes zero sense to expend valuable capital to purchase generators, offices, WC’s etc. As well, each project is different so flexibility, customization and ease of transport is key.



“Our large competitive advantage is the ability to what we refer to as ‘combo technology,” states Joel Bardwell, Senior Manager at Hart. “Whether on a skid or one of our proprietary portable trailers, we can deliver not only the equipment required, but customize it to be the most cost effective. Customers appreciate the approach and with our ongoing R&D and patent/patent pending profile, both served us well during the downturn and positions us well for the rapidly increasing business, both from previous and new clients.”

Hart currently has 6 locations that are strategically located throughout west central and northern Alberta and northeastern British Columbia. These 6 locations have allowed Hart to establish 6 complimentary “service circles” that slightly overlap and allow Hart to deliver oilfield site set-up services and equipment rentals efficiently to its customers as well as respond quickly to requests for service or repairs to its equipment when required.

Early on, Hart realized that the uniqueness of its approach warranted patent filings for equipment as well as industrial designs. With approximately 25 equally divided between Canada and the US, the practice both cements Hart’s reputation as an innovator as well as protect the Company and Enterprise shareholders from interlopers.

There are always interlopers.



It should also be noted that Hart does not sell the custom equipment. Hart is constantly developing equipment to add to its robust and state of the art rental pool: And all with
safety the primary consideration.

Just as with all the Enterprise Group’s subsidiaries, attention to detail is a given. Reactive and proactive to customer needs is what cuts it out of what is already a small herd. Whether resource, municipal needs, pipelines or any other infrastructure pursuit, that word - infrastructure - should be reflected to a greater or lesser degree in every portfolio. US peers are hitting new highs and others, such as Enterprise’s share price is being wrongly assaulted by a volatile oil price.

The bottom line is that over the years Enterprise has made savvy, money making purchases and sales. TC Backhoe sold in 2016 for approximately C$20 million. The Company was purchased in 2007 for C$12 million and under the Enterprise umbrella generated $150 million. The sale was done during the recent downturn, but had been planned previously and drastically lowered and improved the Company’s financials.

Having successfully steered through a blistering downturn, which seems to have unfairly punish a stock that has a breakup of C$0.85 but is trading at C$0.30, it seems a good addition to a junior portfolio.

Investors will also note that as the Company is traded on the TSX that adds to a list of bonafides to Enterprise that investors would be wise to take stock.



Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Baystreet.ca assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Baystreet.ca has been compensated ten thousand dollars for its efforts in distributing the TSX:E profile on its web site and distributing it to its database of subscribers. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report. ]]>
<![CDATA[WADA Lifts CBD Ban for Professional Athletes and their Doctors]]>Thu, 12 Oct 2017 08:02:09 ESThttp://www.baystreet.ca/articles.aspx?id=38458
The World Anti-Doping Agency (WADA) just removed hemp-derived cannabidiol (CBD) from its 2018 List of Prohibited Substances, freeing up athletes in the largest international athletic associations in the world like the IOC and FIFA as well as major sports leagues like UFC, NCAA, NFL, NBA, NHL, MLB, and many more to use CBD-infused products as to treat pain and inflammation based disorders.

As WADA is a global governing body, now athletes around the world can use CBD to treat pain, inflammation and injuries, without the risk of league suspension or a loss of sponsors. Professional athletes around the world can now use Phivida’s CBD infused functional foods and natural health brands, free from WADA restrictions, for the first time in the history of competitive sports.

Cannabinoids have just got mainstream, starting with the major leagues. But it’s investors, and CBD-infused infused functional foods and natural health products brands that stand to benefit the most.

According to Allied Research, the global anti-Inflammatory therapeutics market is projected to top $106 Billion USD by 2020, dominated by OTC drugs like Ibuprofen ($14.2 billion USD by 2022). The US opiate drug as an additional $17.7 billion USD by 2021 dominated by Oxycontin, Percocet and Vicodin. Both the NSAIDs and opiate markets are dominated by pain and inflammation pharmaceutical mogul Bayer (BAYN.DE), with a market capital of over $96 billion.

Cannabidiol is widely studied as a powerful anti-inflammatory and was even part of a US Department of Health patent application for anti-oxidant and neuroprotectant properties.

RISING DEMAND FOR CBD-INFUSED PRODUCTS

Timing the market is vital for maximizing investment returns. There is no better example of fortunate timing than WADA’s announcement coinciding with the launch of Phivida Holdings Inc.’s CBD-infused functional foods and natural health products, and the filing of prospectus for an initial public offering and an application to list its class A shares on the Canadian Securities Exchange (CSE).

As a premiere CBD brand, Phivida is perfectly positioned to capture a leadership market share in this emerging global natural health products market. The Phivida IPO offers investors with exposure to three major growth trends within a global health and wellness $1 Trillion USD in 2017.

Bloomberg predicts US cannabinoid products as a $50 billion USD market by 2020. Within the cannabinoids market, Phivida has created its own unique products category – functional CBD edibles.

High Times magazine produces a top ten edibles list and this year six of them were cannabinoid infused beverages. Phivida specializes in the CBD beverages avoiding a saturated confectionary soft drinks market with functional CBD iced teas, CBD protein shakes and CBD vitamin juices.

Health care practitioners, and now sports medicine professionals, and major nutraceutical distributors cite the paradigm shift from chemical based pharmaceuticals to phytonutraceuticals.

Supplements as a whole market is exploding, having gone from a $37 billion US estimate in 2015, to an expectation of $220 billion globally by 2022.

Nutrition Business Journal cites the two fastest growing categories as; meal replacements (14.8%) and sports nutrition (11.6%), two flagship CBD product lines at Phivida – both infused with a high dose of cannabidiol. Phivida’s nanoencapsulation technology loads CBD into a protective, hydrophilic, liposomal membrane that bonds better with cells. The result is a faster acting longer lasting absorption rates, with up to 400% more bioavailability and a timed release for enhanced duration in the bloodstream, and solubility.

Functional foods have surpassed traditional food topping a $100 billion USD back in 2015. The functional food industry is in the process of a massive consolidation as over $10 billion USD of new M&A deals were completed in 2016 alone.

Major food companies are acquiring new organic and functional food brands at a staggering rate, lead by multi-national conglomerates such as Hains Celestial (NASDAQ: HAIN), PepsiCo (NYSE:PEP) and General Mills (NYSE:GIS).

It’s no wonder that major retailers in both the grocery sector, and the nutritional supplements space are champing at the bit to grow their selection of products for consumers.

WADA’s prohibition lift may be the catalyst needed for supplement giant GNC Holdings Inc. (NYSE:GNC) to get its year back on track. Having fallen from over $20 to just over $8 within the year, the ability to introduce new lines of nutritional supplements with pain relieving qualities could be a shot in the arm for GNC.

Whereas major grocery and pharmacy chains, such as Canadian retail giant Loblaw Companies Inc. (TSX:L)(OTC:LBLCF), which owns the well-established Shoppers Drug Mart chain. Unlike GNC, which to-date has been reluctant to carry CBD products in-store, Shoppers Drug Mart has been very open about its willingness to carry CBD and marijuana-related products on its shelves.

It’s still to be determined when and if that same level of acceptance will be seen on the US side of the border. GNC currently doesn’t carry any CBD-infused products, selling only hemp proteins as a remotely close cousin. Nor is CVS Health Corporation (NYSE:CVS), yet.

Online mega-retailer Amazon.com Inc. (NASDAQ:AMZN) is already selling CBD products. On track to hit the very first $1 trillion valuation, Amazon is ahead of the curve on the blossoming CBD sector.

Whole Foods CEO John Mackey stated he would support cannabinoid products sold in Wholefoods “if only the plant was legal to use and the local community approved.”

Not only is CBD-Hemp Oil extract legal under the Farm Bill, but WADA’s new rules has the potential for a massive demand from professional athletes, sports medicine practitioners and alternative health care practitioners and the everyday active health conscious consumer. It looks like John might get his wish.

Plant-based supplements like CBD are no longer limited to the estimated 17,500 licensed alternative health care practitioners, as majority of supplements are now sold through big box FCMD (food, club, mass and drug) retail locations.

Walgreens, CVS and Walmart combined for a total of 27,087 on-site pharmacists at 15,208 stores across the United States. With Amazon’s acquisition of Wholefoods earlier this year, it’s clear that the majors are looking to capitalize on the health-conscious consumer.

Now it’s a matter of CBD’s true market infiltration to take hold, and for producers to begin stocking only the best CBD infused FFNHP formulations.

Primed and ready to supply these retailers with timely product, Phivida boasts an entire line of CBD functional foods and natural health products, doctor formulated for enhanced athletic performance and everyday preventative health for active families.

INDUSTRY AND ORGANIC ADVANTAGE

Totally legal, and boasting a laundry list of health benefits, cannabidiol (CBD) is making waves through the food and beverage industry in the form of several new products.

So it’s no wonder that any new producer of CBD products will want to seek out the expertise of those already familiar with the food and beverage industry.

Assembling an impressive array of talent, Phivida’s management team is built to master not only its formulation, but also its branding and retail distribution.

Among the names on the company’s deck are Directors Bill Ciprick and James Bailey, who each come with decades of branding and distribution experience for industry heavy-hitters, such as Proctor and Gamble Health Care, and Red Bull Canada.

But for the consumer, the most important aspect to consider beyond retail availability is that of the product’s organic, whole-plant blends and formulations.

Phivida infuses full-spectrum CBD Hemp Oil extracts into special blends of functional foods and natural health products (FFNHP). All nanoencapsulated CBD used in Phivida’s products is hemp-derived from licensed hemp farms and federally legal and eligible for sale in any retail channel.

The company’s CBD-infused functional beverages are nanoencapsulated for enhanced bioavailability, and doctor-formulated for targeted outcomes. Phivida boasts quality-, and safety-tested products that are cGMP manufactured to the highest quality assurance standards.

Phivida CBD Vitamin Drinks use certified organic and plant-based ingredients. Phivida’s CBD infusions are also vegan, gluten- and soy-free with no sugar added and contain at least 35% RDA of Vitamin B complex and Vitamin C.

Other key sports performance ingredients include premium electrolyte replacements, glutamine for muscle, bone and joint repair, resveratrol for added anti-oxidants, blended in an all-natural fruit and vegetable puree with no artificial colours or flavours added.

Former President of the BC College of Naturopaths, Dr. Brian Martin, states; “Phivida offers legal, clinical grade, CBD, third-party tested, and safe for practitioners to recommend to athletes and patients.” Marijuana is federally illegal in the United States, but hemp provides a legal option for clinicians. WADA’s new ruling now opens CBD to team physicians, physiotherapists, nutritionists and kinesiologists. “Phivida is a high-quality brand for athletes who need healthier, non-addictive treatments for pain and inflammation,” said Dr. Martin.

WADA’s now-positive stance on CBD represents a great opportunity for Phivida. Competitive athletes in high-impact sports like football, hockey and mixed martial arts are often plagued with a lifetime of debilitating physical injuries and mental health conditions.

Phivida’s CBD infusions give athletes, their trainers, and medical staff a whole-plant nutraceutical alternative to highly addictive opiate pharmaceuticals to treat chronic pain and inflammation from these injuries and afflictions.

ATHLETIC ENDORSEMENT

Earlier this year, the New York Times published a neuropathology study that found that 99% of former NFL players tested positive for Chronic Traumatic Encephalopathy (CTE). The NFL supports the NFL Players Association’s (NFLPA) study on the use of cannabinoids to treat chronic pain inflammation based disorders, like CTE, according to a Sports Illustrated article published on August 1st, 2017.

The NFLPA was coincided by the launch of the Your Mind Your Body Campaign designed to equip current and former players with the tools needed to achieve a healthy lifestyle, both physically and mentally and encourages an open dialogue on pressing health and safety issues, including CTE, and mental health.

Use of cannabinoid-based alternatives to opiates is not a new issue for the NFL. Many former players have become advocates for CBD as alternatives to narcotics, including former Baltimore Raven Eugene Monroe, Denver Bronco Jake Plummer, Chicago Bear Jim McMahon, and Ricky Williams who publicly stated a belief that “60-70% of all NFL athletes use medicinal marijuana”.

Despite the fact that both the NFLPA and NFL endorse a study of marijuana as a potential pain-management tool, the NFL currently suspends players who test positive for the drug and modified the threshold for a positive test for marijuana (i.e. THC). Finally, WADA’s new adoption of CBD as an approved substance, gives the NFL and its players hope for immediate relief, without controversy.

Phivida’s CBD-infused functional foods and natural health products are formulated with a special blend of nutraceuticals for enhanced athletic performance, and infused with a therapeutic dose of nanoencapsulated cannabidiol from hemp.

"This pain is never going away. My body is damaged," Eugene Monroe, 30, stated in a Washington Post article. "I have to manage it somehow. Managing it with pills was slowly killing me.”

With the lift on the CBD ban, WADA is finally taking sensible action on behalf of the athletes it is tasked to protect.

“Cannabidiol is no longer prohibited,” WADA said, maintaining that THC will remain as a banned substance. WADA cited the reason for the removal of cannabidiol from the banned list was because “it is not a cannabimimetic and does not mimic the effects of THC.”

WADA further clarified: “THC is still a prohibited substance.”

THC or tetrahydrocannabinol is the psychotropic chemical compound in marijuana that contributes to euphoric effects. Many CBD products on the market are marijuana derived and contain THC.

Purity levels in CBD-infused products will give an industry advantage to those producers that can utilize the most CBD, without delivering any THC.

Phivida’s nanoencapsulated CBD-Hemp Oil extracts, edibles and infusions, are federally legal, derived from Farm-Bill-compliant farms, and are now 100% WADA-compliant sources for cannabidiol. As well, they’re coming to a store near you.

Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Baystreet.ca assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Baystreet.ca has been compensated eight hundred dollars for its efforts in distributing the Phivida article. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report.
]]>
<![CDATA[Valeant (VRX) Cleans Up its Debt]]>Thu, 12 Oct 2017 07:40:19 ESThttp://www.baystreet.ca/articles.aspx?id=38457
Valeant, on October 3, issued a $1-billion debt offering that lower the total upcoming maturities.

Valeant priced its $1-billion principal amount of 5.5% senior notes due in 2025. It will use the proceeds to roll over existing debt. The issuance is not trivial: the lower interest will save the company money while simultaneously pushing out the maturity date.

The low interest rate offered suggests the market has a healthy appetite for Valeant’s debt, so the fear of any bankruptcy is now off the table. Valeant now has around $26 billion in debt and $24 billion net of cash. In June, the company’s net debt was $26.7 billion. The sale of Dendreon raised $811 million, while iNova brought in $923 million. The net effect is that Valeant will have $3.9 billion maturing in 2020.

Assuming Valeant generates $1 billion in free cash flow, the company’s interest on debt in 2020 are covered. It sets the stage for refinancing for the debt due in 2021 and beyond.
]]>
<![CDATA[Athersys Hikes on MultiStem Hookup with Japanese Firm ]]>Wed, 11 Oct 2017 12:24:52 ESThttp://www.baystreet.ca/articles.aspx?id=38456Based on the agreement, Athersys and NCLi will engage in technology transfer activities at NCLi’s facility in Japan, and NCLi will begin contract manufacturing support for commercial development of the product in Japan. Athersys’ collaborator, HEALIOS K.K. (Healios), has an exclusive license to develop and market MultiStem in Japan for ischemic stroke, and is currently conducting its registrational clinical study, TREASURE, in Japan.

A news release issued Wednesday claimed therapeutic treatment with MultiStem may extend the stroke treatment window to 36 hours from the current three to four-and-a-half hours with existing standard of care, which would enable many more stroke patients to receive treatment than under the current standard of care and may also meaningfully enhance patient recovery.
Currently, there are nearly 17 million people that suffer a stroke globally and, on average, someone in the United States has a stroke every 40 seconds.
Athersys shares gained 11 cents, or 4.9%, midday Wednesday to $2.34, within a 52-week trading range of $1.02 to $2.63.
]]>
<![CDATA[Delta Gains Altitude on Q3 Earnings]]>Wed, 11 Oct 2017 11:12:22 ESThttp://www.baystreet.ca/articles.aspx?id=38455The number-two U.S. airline reported adjusted earnings per share of $1.57, beating analysts' expectations of $1.53 a share for a quarter that ended with hurricanes that crippled operations.

Earnings per share were about 8% lower over the year-earlier period.

The airline posted quarterly revenue of $11.06 billion, slightly higher than expectations for $11.03 billion in the three months ended in September.

Delta's passenger revenue per available seat mile — a key income metric — rose 1.9%, in line with the airline's updated forecast earlier last month. It said it expects a 2% to 4% increase in passenger unit revenue in the fourth quarter, but warned that higher fuel costs would likely crimp operating margins for the last three months of the year.

Delta posted higher revenue in domestic and Latin American and trans-Atlantic operations, despite powerful storms in the Southern U.S. in August and September.

Delta executives will likely address the impact from deadly storms that hit carriers' hubs late this summer, as well as a bitter trade dispute between two Delta suppliers, Boeing and Canada's Bombardier.

Hurricane Irma, which struck Florida and Delta's hub in Atlanta, forced the airline to cancel more than 2,000 flights.

Delta shares began Wednesday’s trading up 37 cents to $53.07
]]>
<![CDATA[BlackRock Rocks Markets on Q3 Figures ]]>Wed, 11 Oct 2017 10:42:55 ESThttp://www.baystreet.ca/articles.aspx?id=38454Total assets under management rose 17% to nearly $6 trillion as net inflows easily beat Wall Street expectations.

Here's how the company's results compare to Wall Street's expectations: EPS came in at $5.92 per share, compared with $5.56 expected. Revenue was $3.233 billion versus $3.096 billion expected.

Total assets under management registered at $5.977 trillion versus experts’ projected $5.94 trillion.
Net inflows were $96 billion versus $71.62 billion expected.
BlackRock also said its iShares exchange-traded funds business saw $52.3 billion in long-term net inflows, led by $33.1 billion in equity inflows. Assets under management for iShares totaled $1.640 trillion, accounting for 27% of BlackRock's total assets.

The company said cash assets rose 6 percent from a year earlier to $425.4 billion.

"One of the greatest problems we still have in the world is how much money is sitting on the sideline," according to CEO Larry Fink. "Even in places like Japan, there's $5 trillion in cash earning negative return. In Germany 72% of savings are in bank accounts. We're seeing some of that unlocked (and), we're seeing people put some of that money to work."

The company's stock has been on fire this year, advancing 21.5%. By comparison, the overall S&P 500 is up about 14% in the period. BlackRock shares have also outperformed the financials sector, which is up 13% in 2017.
BlackRock shares opened Wednesday up $2.80 to $468.29 ]]>
<![CDATA[Emblem Positioned to be Disruptive in the Medical Cannabis Industry]]>Wed, 11 Oct 2017 08:44:45 ESThttp://www.baystreet.ca/articles.aspx?id=38453
First, it has become apparent that for the foreseeable future, a few select Canadian marijuana companies will lead the sector growth, particularly over the US.


Second, the virtually unlimited growth in the space will and is being realized through the pharmaceutical developments, particularly in the pain, sleep and anxiety markets. Pain markets alone are $60 billion and will rise over 30% to $83 billion by 2024. Pain and sleep markets are two of the largest component markets.

Key to this growth at companies such as Emblem (TSXV:EMC) is when society embraces marijuana as what could well be the first line of defense and treatment for many afflictions, including the devastating opiate crisis.

“Emblem is focused on developing mainstream medical therapies to deliver consistent, 12-hour relief, with reduced side effects.,” states Gordon Fox, CEO Emblem Corp. “Canada is one of the few jurisdictions in the world –including the USA--with a path to regulatory approval of cannabinoid based medication. ACMPR has mechanisms for approval and these mechanisms are currently being expanded. The Canadian medical community can participate in research and clinical trials and share data and results across provincial boundaries.

With our recently announced exclusive arrangement with CanntabTherapeutics, Emblem is executing to plan.”

The Canntab Deal

Very simply, Canntab has the proprietary sustained release formulation: Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) to cultivate and sell medical marijuana.

Canada is one of the few jurisdictions in the world with a path to regulatory approval of cannabinoid based medication.

- The current medical cannabis market in Canada is about $400 million. It is searching for better dosage formats. Simple oils have grown to about 35% of the market in less than a year. More appropriate dosage formats are expected to have comparable effects in the market.

- Currently, Cannabis tends to require re-dosing. A titratable, sustained release formulation would have substantial appeal in the chronic neuropathic pain market. Anecdotally, that segment represents a reasonable percentage of the current$400 million medical cannabis market.

- The Canadian non-cannabis chronic pain pharmaceutical market is over $500 million and dominated by opioids and is expected to reach $42.16 billion worldwide by 2021. A cannabinoid based sustained release product has potential to enter that market.



From Emblem’s October 3rd Press Release:

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use.

The Agreement grants to Emblem the exclusive right in Canada to Canntab’s patents and know-how for the purpose of developing, commercializing, using, selling, and offering the Sustained Release Product for sale under the Emblem brand. The License does not include the right to import or export the Product. The Sustained Release Products will be manufactured by Emblem or by Canntab, after Canntab receives appropriate licensing allowing such manufacture.

As per other Royalty Agreements in the Pharmaceutical Sector terms weren’t disclosed other than ‘double digit” royalty. To be clear this relationship with Canntab is extremely favorable to Emblem.

It cannot be overstated how important a develop this is for patients. Instead of waiting 5-10 years for a therapy to get to patients, cannabis based products take mere months. There is substantial evidence that cannabinoids are effective for the treatment of a number of conditions including (i) chronic pain (ii) nausea, (iii) anxiety and sleep disorders, and (iv) spasticity in patients with Multiple Sclerosis.

The Global Opiate Crisis

While therapies will address particular conditions, anecdotally many patients know and have expressed the efficacy, ease of use and lack of side effects in pain management particularly.

Emblem plans to bring products to deal with neurological pain by fall 2018. Once the 12- hour delivery protocol is established, many afflictions can be addressed via the proper strain and titration.

Investors need to embrace the potential of this market and acquire some exposure. Choose carefully as there are many companies who have and will likely fail or price themselves out of the market.

Emblem’s business plan sets three divisions to be profit centres. From ongoing reasonable to maximum growth:

- Dried flower is the commodity space which provides superior, but generic product

- High quality strains (think aged single malt scotch versus JW Black) for the aficionado

- Top quality strains for ongoing therapeutics’ development.

Margins increase exponentially from dried flower to medical strains. Emblem (TSXV:EMC) is focused on the two markets above dried flower, although will be a major force in all three.

Marijuana Market Maturing Slightly. Invest Carefully, but Invest

The Marijuana space has matured somewhat from mining guys seeing a quick turn in fortunes by announcing some hair-brained participation to get their languishing stock prices up.

Then there the companies who conclude that more marijuana is better and are growing as much as they can.

Finally, there are a few companies, such as Emblem that have a solid growth plan and are not afraid to state their corporate intentions. Many comparisons are made to the UK’s GW Pharma as the direction a developing company should travel.

GW’s Sativex is approved for the treatment of spasticity due to multiple sclerosis in 30 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. GW’s ADS on NASDAQ in 2013 came at $8.90. Last trade at this writing was $114.07.

Fun Facts

- Some plant biologists got their early weed (60’s, 70’s) experience by serving time for possession, etc.

- Lots of anecdotal evidence that Big Pharma continues to pay doctors to keep their products at the forefront

The five companies that disclosed what they paid doctors over a six-month period (July to December 2016) were:

- AbbVie (NYSE:ABBV) : $4,104,000

- Novartis (NYSE:NVS) : $3,645,026

- Amgen (NASDAQ:AMGN) : $2,365,000

- Bristol-Myers Squibb (NYSE:BMY) : $1,388,187

- Gilead (NASDAQ: GILD) : $539,761



That alone should give Marijuana companies such as Emblem a place in your speculative portfolio.

Oh, yes. 10 percent of patients suffer from Trypanophobia. That fear keeps 20 percent of that number to never seek medical attention. Look it up…

Perhaps with the inevitable insertion of Marijuana based therapies should reduce or eliminate that number.

And how would Big Pharma ‘payola’ doctors for such a readily available and efficacious therapy? Bueller?

Next couple of decades should be interesting; with less pain, more sleep, relief from chronic disease as well as lives saved.

Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Baystreet.ca assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Baystreet.ca has been compensated four thousand dollars for its efforts in distributing the TSXV:EMC profile on its web site and distributing it to its database of subscribers. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report. ]]>
<![CDATA[AnaptysBio Makes Waves on Trial Data ]]>Tue, 10 Oct 2017 03:25:01 ESThttp://www.baystreet.ca/articles.aspx?id=38452Said CEO Hamza Suria, “we are very encouraged by the efficacy results to date in this Phase 2a study, which exemplify our strategic focus on developing first-in-class anti-inflammatory antibody therapeutics to help patients suffering from debilitating inflammatory diseases.

“We look forward to further advancing the development of ANB020 for the treatment of patients with atopic diseases.”

The Phase 2a study is currently ongoing and EASI scores will be assessed for each patient up to 140 days post-ANB020 treatment. The company plans to report full data from this trial at a medical conference following study completion.

AnaptysBio is a clinical-stage biotechnology company developing what it calls “first-in-class antibody product candidates focused on unmet medical needs in inflammation”.

Its shares neared the close Tuesday up in the stratosphere, leaping in price $31.02, or 88.6%, to $66.02.
]]>
<![CDATA[Wal-Mart Hikes on Share Buyback Program]]>Tue, 10 Oct 2017 11:30:29 ESThttp://www.baystreet.ca/articles.aspx?id=38451Wal-Mart also unveiled a $20-billion share repurchase program to replace its existing plan. The company says the new authorization will be used over a two-year period.

The big-box retailer explained it will continue to focus on remodeling existing stores and incorporating "digital experiences" in place of building new locations.

Ahead of its annual investor day in Bentonville, Arkansas, Wal-Mart said it expects its U.S. e-commerce business to grow sales by roughly 40% in fiscal 2019. Online transactions surged 60% during the second quarter of this year, the retailer declared in August.

The company still expects adjusted earnings per share for the fiscal year 2018 to fall between $4.30 and $4.40.

For fiscal 2019, Wal-Mart said it expects earnings to increase about 5% year over year. Net sales for fiscal 2019 are expected to grow close to 3%, driven by same-store and e-commerce sales growth, the company added.

In fiscal 2019, across the U.S., Walmart will open fewer than 15 Supercenters and fewer than 10 of its Neighborhood Markets.

For fiscal years 2018 and 2019 combined, Wal-Mart is calling for capital expenditures to be about $11 billion, with e-commerce investments going toward enhancing the retailer's supply chain. Wal-Mart's international business will also invest more in fulfillment capabilities.

Shares in Wal-Mart galloped $3.53, or 4.4%, to $84.06
]]>